trivalent influenza vaccine

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

InfluenzaType 2 Diabetes MellitusAcute Lymphoblastic LeukemiaChronic Lymphocytic Leukemia

1053 competitors in Influenza

#DrugCompanyPhaseTrials

1

trivalent influenza vaccine

Sinovac Biotech Co., Ltd

Approved

272

Fluzone

Sanofi

Preclinical

163

Crestor

AstraZeneca

Preclinical

14

Trexall

Alnylam Pharmaceuticals

Preclinical

15

Quadrivalent Influenza Vaccine

Sanofi

Preclinical

306

COMIRNATY

Pfizer

Preclinical

17

Focetria

CChiltern Pesquisa Clinica Ltda

Preclinical

18

Influenza A/H5N1

NNational Institute of Allergy and Infectious Diseases (NIAID)

Preclinical

149

PD-1/PD-L1 Inhibitors

CChuangzhen Chen

Preclinical

110

Fluvirin

Novartis

Preclinical

3Show 11 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Influenza27 trials

High-Dose Trivalent Influenza Vaccine in Inducing Immune Response Patients With Central Nervous System Tumors

Completed·WWake Forest University Health Sciences·Phase 1·NCT01941758·28 enrolled

Evaluation of Antibody Response to High-Dose Seasonal Influenza Vaccination in Patients With Myeloid Malignancy Receiving Chemotherapy and Healthy Volunteers

Completed·RRoswell Park Cancer Institute·Phase 1·NCT04484532·130 enrolled

Influenza Vaccination of HIV Infected Pregnant Women: Safety and Immunogenicity

Completed·UUniversity of Witwatersrand, South Africa·Phase 2/3·NCT01306682·194 enrolled

Show 24 more trials

Influenza Vaccination for Flu Prevention in Patients With Plasma Cell Disorders

Completed·EEmory University·Phase 4·NCT04080531·165 enrolled

A Phase I/IIa Study of GC3110A (Quadrivalent Influenza Vaccine)

Completed·GGreen Cross Corporation·Phase 1/2·NCT02121782·84 enrolled

Effect of Age and Prior Immunity to Response to Seasonal Influenza Vaccines in Children

Completed·UUniversity of Rochester·Phase 4·NCT01246999·34 enrolled

Trivalent Influenza Vaccine in Preventing Flu in Patients With Central Nervous System Tumors

Completed·WWake Forest University Health Sciences··NCT01474174·38 enrolled

Protectivity and Safety of Quadrivalent Influenza HA Vaccine in Indonesian Population

Completed·PPT Bio Farma·Phase 2·NCT03336593·810 enrolled

Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in Adults for the 2015-2016 Season

Completed·AstraZeneca·Phase 4·NCT02473510·301 enrolled

Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in Adults

Completed·AstraZeneca·Phase 4·NCT01859143·300 enrolled

Influenza Vaccine Trial in HIV Uninfected Pregnant Women

Completed·UUniversity of Witwatersrand, South Africa·Phase 3·NCT01306669·2,116 enrolled

Safety, Tolerability, and Immunogenicity of Different Combinations of Trivalent Influenza Vaccine Varying Influenza Antigen Dose, Adjuvant Dose, and Route of Administration in Healthy Elderly Individuals Ages 65 Years and Older

Completed·SSeqirus·Phase 1·NCT00848848·450 enrolled

Flu Vaccine in Preventing Influenza Infection in Healthy Volunteers and in Patients Who Have Undergone Stem Cell Transplant

Completed·—··NCT00964821·459 enrolled

Immunogenicity and Safety of Trivalent Influenza Vaccine in Pregnant and Nonpregnant HIV Uninfected Women

Completed·UUniversity of Witwatersrand, South Africa·Phase 4·NCT01816464·150 enrolled

Adjuvanted Influenza Vaccination in U.S. Nursing Homes

Completed·IInsight Therapeutics, LLC·Phase 4·NCT02882100·823 enrolled

Study of Evaluating Safety and Immunogenicity of 23-Valent Pneumococcal Polysaccharide Vaccine With Influenza Vaccine in Children and Adults

Completed·JJiangsu Province Centers for Disease Control and Prevention·Phase 4·NCT02062281·2,225 enrolled

Safety, Tolerability, and Immunogenicity of GC3106 (Quadrivalent Cell-culture Based Influenza Vaccine)

Completed·GGreen Cross Corporation·Phase 1/2·NCT02249221·84 enrolled

Immunogenicity and Safety of Different Dosing Schedules of Trivalent Influenza Vaccine in HIV-infected Pregnant Women

Completed·UUniversity of Witwatersrand, South Africa·Phase 3·NCT01527825·800 enrolled

A Clinical Trial of Quadrivalent Influenza Vaccine in Healthy Subjects Aged 6 to 35 Months

Completed·Sinovac Biotech Co., Ltd·Phase 3·NCT05245552·217 enrolled

A Study to Evaluate the Immunogenicity and Safety of bioCSL Quadrivalent Influenza Vaccine (QIV) in Adults Aged 18 Years and Above.

Completed·SSeqirus·Phase 3·NCT02214225·3,484 enrolled

Clinical Trial to Evaluate the Safety and Immunogenicity of Quadrivalent Influenza Vaccine (15µg/0.5ml)

Completed·Sinovac Biotech Co., Ltd·Phase 3·NCT03853993·2,380 enrolled

A Phase III Clinical Trial of Quadrivalent Influenza Vaccine in Healthy Subjects Aged 6 to 35 Months

Completed·Sinovac Biotech Co., Ltd·Phase 3·NCT06049927·3,300 enrolled

Safety and Immunogenicity of a Four Influenza Vaccines in Children Ages 6 Months Old to Less Than 48 Months Old

Completed·SSeqirus·Phase 1/2·NCT02035696·671 enrolled

Systems Biology of Trivalent Influenza Vaccine (TIV) in Young and Elderly

Completed·EEmory University·N/A·NCT01232868·66 enrolled

Clinical Trial to Evaluate the Safety and Immunogenicity of Quadrivalent Influenza Vaccine (7.5μg/0.25ml)

Completed·Sinovac Biotech Co., Ltd·Phase 3·NCT03859141·2,340 enrolled

A Study to Assess the Immunogenicity and Safety of a Trivalent Influenza Vaccine Containing the 2013/2014 Formulation of Enzira® Vaccine in Healthy Volunteers

Completed·SSeqirus·Phase 4·NCT01863433·120 enrolled

Response to Influenza Vaccine in Patients With Non-Hematologic Malignancies Receiving Chemotherapy

Terminated·WWashington University School of Medicine·Phase 1·NCT01695733·21 enrolled

Flu Vaccine2 trials

Cholecalciferol and Flu Vaccine in Treating Healthy Participants

Terminated·RRoswell Park Cancer Institute·N/A·NCT01561989·11 enrolled

Safe Administration of Flu Vaccine to Egg Allergic Children

Completed·UUniversity of Michigan·N/A·NCT01264601·31 enrolled

Type 2 Diabetes Mellitus1 trial

Effectiveness of Trivalent Influenza Vaccine (TIV) in Type 2 Diabetes Mellitus (T2DM) Patients With and Without Complications of Chronic Kidney Disease (CKD)

Completed·UUniversitas Padjadjaran·Phase 4·NCT06252051·76 enrolled

Chronic Lymphocytic Leukemia1 trial

Ibrutinib as an Immune Modulating Agent for Patients With Asymptomatic, High-risk CLL/SLL Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Active, not recruiting·JJennifer Woyach·Phase 2·NCT02518555·42 enrolled

Immune System1 trial

Qualitative, Qualitative, and Functional Studies Over the First Year in Measuring Immune System Response During the First Year of Therapy in Patients With Brain Tumors

Completed·WWake Forest University Health Sciences··NCT02747407·55 enrolled

Details

Drug Info

Related News